Investors should monitor upcoming Q2 2026 data readouts from the REVEAL Phase 1/2 trial and completion of dosing in pivotal trials, which could serve as key catalysts for BLA submission. The expanded cash runway into 2028 reduces near-term dilution risk.
Price Chart
Executive Summary
Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its TSHA-102 program for Rett syndrome, including dosing in pivotal trials, FDA alignment on BLA-enabling strategies, and a favorable safety profile. Revenue increased to $9.77 million, though net loss widened to $109.0 million due to higher R&D and administrative expenses. The company has $319.8 million in cash, sufficient to fund operations into 2028.
Key Financial Metrics
Key Facts
- Revenue increased 17.3% YoY to $9.77 million in 2025
- Net loss widened to $109.0 million in 2025 from $89.3 million in 2024
- R&D expenses rose 30.9% to $86.4 million, driven by clinical trial and manufacturing costs
- Cash and cash equivalents totaled $319.8 million as of December 31, 2025
- FDA cleared initiation of ASPIRE trial and provided written alignment on CMC and BLA strategy
- No treatment-related SAEs or DLTs observed in REVEAL trials as of March 2026
- Dosing in REVEAL pivotal and ASPIRE trials on track for completion in Q2 2026
Financial Impact
Revenue grew 17.3% to $9.77 million, but net loss increased by $19.7 million due to higher R&D and G&A spending. Cash burn was significant, though offset by $50 million raised via ATM, leaving $319.8 million in cash.
Risk Factors
- Clinical development risk: TSHA-102 remains investigational with no guarantee of regulatory approval
- Cash burn remains high; future equity raises could lead to dilution despite current runway
- Revenue is minimal and non-recurring (likely from collaborations), not indicative of commercial product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258910 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.66 (−27.17%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.66 (−26.42%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.66 (+26.42%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.66 (+24.88%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.66 (−15.18%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.66 (−25.60%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.66 (−25.95%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.66 (−30.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access